Breaks Categories: News

TuesdayFeb 20, 2024 12:13 pm

BioMedNewsBreaks — Astiva Health Opens Doors to New LA-Koreatown Activity Center, Marks ‘Testament’ to Empowering Seniors

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, has opened a new facility in Los Angeles. The company is celebrating the Dec. 16, 2023, opening of its Los Angeles-Koreatown Activity Center. The grand-opening ceremony, which marked a milestone for Astiva in its efforts to serve the senior community of Koreatown, included a ribbon cutting by Congresswoman Michelle Steel. According to the announcement, the new activity center will offer health education and wellness activities for seniors in Koreatown and is designed to be a center for senior care. The new center,…

Continue Reading

ThursdayFeb 15, 2024 2:49 pm

BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes on $10M Public Offering

Sunshine Biopharma (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, has closed on a firm commitment underwritten public offering. The offering is comprised of 71,428,571 units, including 26,428,571 common units and 45,000,000 prefunded units. According to the announcement, the offering is projected to result in approximately $10 million gross proceeds, before the deduction of underwriting discounts and other estimated expenses. Sunshine Biopharma also granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock, prefunded warrants and Series A warrants or Series B warrants sold…

Continue Reading

ThursdayFeb 15, 2024 1:52 pm

BioMedNewsBreaks – Datasea Inc. (NASDAQ: DTSS) Collaborates to Bring Unique Platform to New Customers

Datasea (NASDAQ: DTSS) is a Nevada incorporated digital technology corporation engaged in innovative business segments for intelligent acoustics and 5G multimodal communication technology in China. The company has announced that on Feb. 2, 2024, Guozhong Times (Beijing) Technology Ltd., a subsidiary of the Chinese operating company contractually controlled by Datasea, has entered into a cooperation agreement with Hangzhou Chongda Technology Co., Ltd. (“Chongda”) to increase the sales of 5G multimodal communication services in China. “We are pleased to enter into this new collaboration as it will help to identify potential customers that need our 5G multimodal communication delivery services and…

Continue Reading

WednesdayFeb 14, 2024 10:44 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for Q2 2024, the period ended Dec. 31, 2023. The company also provided a corporate update, including plans to advance two preclinical programs in Alzheimer's and age-related macular degeneration. Highlights of the report included that the company closed the 2023 calendar year in a cash position of $9.5 million and with 164% revenue growth in business subsidiary, BayMedica. “This period was another strong operational quarter for the company, as we expanded our pharmaceutical pipeline with…

Continue Reading

TuesdayFeb 13, 2024 2:17 pm

BioMedNewsBreaks – Renovaro Inc. (NASDAQ: RENB) Fusing AI and Biotech to Accelerate Personalized Medicine, GEDiCube, Cyclomics Enter LOI to ‘Change the Field’

Renovaro (NASDAQ: RENB) today announced the completion of its acquisition of GEDi Cube Intl Ltd. (“GEDiCube”). Renovaro, which means renew, combines the power of the AI Health Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech platform of Renovaro Biosciences to accelerate precision, personalized medicine, marking a new era in healthcare innovation. According to the announcement, the two subsidiaries will be under the parent organization, which was renamed Renovaro Inc. “We believe this combination marks a significant milestone in the journey of personalized medicine,” said Renovaro’s CEO Mark Dybul, MD. “Together, we believe that we are poised to…

Continue Reading

TuesdayFeb 13, 2024 2:01 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head of business development and sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as marketing and commercial excellence lead for cell and gene therapies for Central, Southern and Eastern Europe. “I am pleased to welcome Liat to Scinai,” said Amir Reichman, Scinai’s CEO. “Her pharmaceutical sales, marketing and leadership experience, in particular in…

Continue Reading

TuesdayFeb 13, 2024 1:07 pm

BioMedNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q2 2024 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is releasing its financial results for Q2 2024, the period ended Dec. 31, 2023. Highlights of the report include a 512% increase in year-to-date revenue, which reached $1,540,000 compared to $301,000 in the same period in 2023; a strong consolidated balance sheet with $37 million in cash and liquid investments; and a year-to-date FY 2024 gross margin increase of 46% from 38% during the same period in 2023. In addition, the company reported that its 1st Detect subsidiary reentered detection and nondetection testing with the U.S. Transportation Security Administration (“TSA”) for cargo…

Continue Reading

FridayFeb 09, 2024 3:05 pm

BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering

Immix Biopharma (NASDAQ: IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, has closed on its previously announced underwritten public offering. The offering consisted of 5,535,055 shares of IMMX common stock, with each share sold at $2.71 per share. Gross proceeds from the offering to ImmixBio are projected to be an estimated $15 million, before standard deductions and expenses. According to the announcement, ImmixBio plans to use funds from the offering for its NXC-201 clinical trials as well as working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as sole…

Continue Reading

FridayFeb 09, 2024 1:27 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered more than two decades of experience in financial leadership roles, primarily in the biotech industry. Most recently, she was vice president of Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS), where she was a key player in the company’s initial public offering process;…

Continue Reading

ThursdayFeb 08, 2024 3:15 pm

BioMedNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering

Revelation Biosciences (NASDAQ: REVB), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, recently announced the closing of its public offering. The offering consisted of 128,470 shares of the company’s common stock and 1,236,530 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 2,730,000 shares of its common stock, at an offering price to the public of $4.53 per share and associated warrant, or $4.5299 per pre-funded warrant and associated warrant. The warrants have an exercise price of $4.53 per share and…

Continue Reading